EUVIMEDEUVIMED entdecken
Crossref

A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD

Claire Kizlik-Masson, Ivan Peyron iD, Stéphane Gangnard, Gaelle Le Goff, Solen M Lenoir, Sandra Damodaran, Marie Clavel, Stéphanie Roullet iD, Véronique Regnault, Antoine Rauch iD, Flavien Vincent, Emmanuelle Jeanpierre und 9 weitere

Blood · 2023

DOI: 10.1182/blood.2022017569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Claire Kizlik-Masson und 20 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Hemostasis, Inflammation & Thrombosis, Unité Mixte de Recherche 1176, Institut National de la Santé et de la Recherche Médicale, Unive…. Hauptthemen laut MEDLINE: von Willebrand Diseases, von Willebrand Disease, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

von Willebrand factor (VWF) is a multimeric protein, the size of which is regulated via ADAMTS13-mediated proteolysis within the A2 domain. We aimed to isolate nanobodies distinguishing between proteolyzed and non-proteolyzed VWF, leading to the identification of a nanobody (designated KB-VWF-D3.1) targeting the A3 domain, the epitope of which overlaps the collagen-binding site. Although KB-VWF-D3.1 binds with similar efficiency to dimeric and multimeric derivatives of VWF, binding to VWF was lost upon proteolysis by ADAMTS13, suggesting that proteolysis in the A2 domain modulates exposure of its epitope in the A3 domain. We therefore used KB-VWF-D3.1 to monitor VWF degradation in plasma samples. Spiking experiments showed that a loss of 10% intact VWF could be detected using this nanobody. By comparing plasma from volunteers to that from congenital von Willebrand disease (VWD) patients, intact-VWF levels were significantly reduced for all VWD types, and most severely in VWD type 2A–group 2, in which mutations promote ADAMTS13-mediated proteolysis. Unexpectedly, we also observed increased proteolysis in some patients with VWD type 1 and VWD type 2M. A significant correlation (r = 0.51, P < .0001) between the relative amount of high–molecular weight multimers and levels of intact VWF was observed. Reduced levels of intact VWF were further found in plasmas from patients with severe aortic stenosis and patients receiving mechanical circulatory support. KB-VWF-D3.1 is thus a nanobody that detects changes in the exposure of its epitope within the collagen-binding site of the A3 domain. In view of its unique characteristics, it has the potential to be used as a diagnostic tool to investigate whether a loss of larger multimers is due to ADAMTS13-mediated proteolysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand Diseasesvon Willebrand Disease, Type 2Humansvon Willebrand FactorProteolysisCollagenEpitopesADAMTS13 Protein

Substanzen

von Willebrand FactorCollagenEpitopesADAMTS13 protein, humanADAMTS13 Protein

Autor:innen und Institutionen

  • Laboratory for Hemostasis, Inflammation & Thrombosis, Unité Mixte de Recherche 1176, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Diagnostica Stago, Unités de recherche & développement, Gennevilliers, France.
  • Inovarion, Paris, France.
  • Université de Lorraine, Laboratory for Acute and Chronic Cardiovascular Deficiency (DCAC), Institut National de la Santé et de la Recherche Médicale Unité 1116, Nancy, France.
  • Université de Lille, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, Institut National de la Santé et de la Recherche Médicale Unité 1011, Lille, France.
  • French Reference Center for von Willebrand Disease (CRMW), Lille, France.

ORCID-Profile: Ivan Peyron, Stéphanie Roullet, Antoine Rauch, Olivier D Christophe, Cécile V Denis, Caterina Casari, Sophie Susen, Peter J Lenting

Zitieren

APA

Kizlik-Masson, C., Peyron, I., Gangnard, S., Le Goff, G., Lenoir, S. M., Damodaran, S., Clavel, M., Roullet, S., Regnault, V., Rauch, A., Vincent, F., Jeanpierre, E., Dupont, A., Ternisien, C., Donnet, T., Christophe, O. D., van Belle, E., Denis, C. V., Casari, C., …, & Lenting, P. J. (2023). A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD. Blood. https://doi.org/10.1182/blood.2022017569

Vancouver

Kizlik-Masson C, Peyron I, Gangnard S, Le Goff G, Lenoir SM, Damodaran S, et al. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD. Blood. 2023. doi:10.1182/blood.2022017569

BibTeX
@article{KizlikMasson2023,
  author = {Kizlik-Masson, Claire and Peyron, Ivan and Gangnard, Stéphane and Le Goff, Gaelle and Lenoir, Solen M and Damodaran, Sandra and Clavel, Marie and Roullet, Stéphanie and Regnault, Véronique and Rauch, Antoine and Vincent, Flavien and Jeanpierre, Emmanuelle and Dupont, Annabelle and Ternisien, Catherine and Donnet, Thibault and Christophe, Olivier D and van Belle, Eric and Denis, Cécile V and Casari, Caterina and Susen, Sophie and Lenting, Peter J},
  title = {A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022017569}
}
Kostenlos starten →